Vaccination of immunocompromised patients

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL. 5, 2012, Pages 93-99

  Ljungman, Per ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Influenza; Pneumococci; Solid organ transplantation; Stem cell transplantation; Vaccination

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; CYTOMEGALOVIRUS VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INFLUENZA A (H1N1); MEASLES; MORBIDITY; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VACCINATION;

EID: 84867353450     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03971.x     Document Type: Review

References (106)

1. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 89-93.
2. Lum L, Noges J, Beatty P et al. Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. Bone Marrow Transplant 1988; 3: 399-406.
3. Ljungman P, Wiklund HM, Duraj V et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990; 162: 496-500.
4. Gerritsen E, Van Tol M, Van't Veer M et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood 1994; 84: 4374-4382.
5. Storek J, Dawson MA, Lim LC et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant 2004; 33: 337-346.
6. Hammarström V, Pauksen K, Björkstrand B, Simonsson B, Öberg G, Ljungman P. Tetanus immunity in autologus bone marrow and blood stem cell transplant patients. Bone Marrow Transplant 1998; 22: 67-72.
7. Engelhard D, Handsher R, Naparstek E et al. Immune responses to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 295-300.
8. Nordoy T, Husebekk A, Aaberge IS et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 2001; 28: 681-687.
9. Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (suppl 4): S258-S262.
10. Feldman S, Malone W, Wilbur R, G S. Pneumococcal vaccination in children with leukemia. Med Pediatr Oncol 1985; 13: 69-72.
11. Robertson JD, Nagesh K, Jowitt SN et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82: 1261-1265.
12. Cherif H, Landgren O, Konradsen HB, Kalin M, Bjorkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine 2006; 24: 75-81.
13. Sinisalo M, Vilpo J, Itala M, Vakevainen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007; 26: 82-87.
14. Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57: 677-684
15. Avanzini M, Carra A, Macccario R et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol 1995; 15: 137-144.
16. Hammarström V, Pauksen K, Azinge J, Öberg G, Ljungman P. The influence of graft versus host reaction on the response to pneumococcal vaccination in bone marrow transplant patients. Support Care Cancer 1993; 1: 195-199.
17. Kumar D, Chen MH, Welsh B et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007; 45: 1576-1582.
18. Molrine DC, Antin JH, Guinan EC et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101: 831-836.
19. Cordonnier C, Labopin M, Chesnel V et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010; 28: 2730-2734.
20. Meisel R, Kuypers L, Dirksen U et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 2322-2326.
21. Pao M, Papadopoulos EB, Chou J et al. Response to pneumococcal (PNCRM7) and Haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2008; 14: 1022-1030.
22. Ljungman P, Cordonnier C, Einsele H et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44: 521-526.
23. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
24. Antin JH, Guinan EC, Avigan D et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 213-222.
25. Kumar D, Humar A, Plevneshi A et al. Invasive pneumococcal disease in solid organ transplant recipients - 10-year prospective population surveillance. Am J Transplant 2007; 7: 1209-1214.
26. Linnemann CJ, First M, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981; 141: 1637-1640.
27. Furth S, Neu A, Case B, Lederman H, Steinhoff M, Fivush B. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996; 128: 99-101.
28. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187: 1639-1645.
29. Kumar D, Chen MH, Wong G et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47: 885-892.
30. Barra A, Cordonnier C, Preziosi MP et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166: 1021-1028.
31. Ljungman P, de La Camara R, Perez-Bercoff L et al. Outcome of pandemic H1N1 infections in haematopoietic stem cell transplant recipients. Haematologica. 2011; 96: 1231-1235.
32. Whimbey E, Elting LS, Couch RB et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 437-440.
33. Ljungman P, de la Camara R, Perez-Bercoff L et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011; 96: 1231-1235.
34. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10: 521-526.
35. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2009; 2: CD006484.
36. Bate J, Yung CF, Hoschler K et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis 2010; 51: e95-e104.
37. Meerveld-Eggink A, de Weerdt O, van der Velden AM et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011; 22: 2031-2035.
38. Mazza JJ, Yale SH, Arrowood JR et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005; 3: 214-220.
39. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma 1999; 32: 369-374.
40. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005; 130: 96-98.
41. van der Velden AM, Mulder AH, Hartkamp A, Diepersloot RJ, van Velzen-Blad H, Biesma DH. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med 2001; 12: 420-424.
42. de Lavallade H, Garland P, Sekine T et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011; 96: 307-314.
43. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1-5.
44. Pauksen K, Linde A, Hammarstrom V et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000; 30: 342-348.
45. Issa NC, Marty FM, Gagne LS et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 434-438.
46. Engelhard D, Zakay-Rones Z, Shapira MY et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011; 29: 1777-1782.
47. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005; 36: 897-900.
48. Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl 2000; 6: 531-542.
49. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001; 7: 311-313.
50. Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant 2004; 14: 346-351.
51. Manuel O, Pascual M, Hoschler K et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52: 248-256.
52. Altamirano-Diaz L, West L, Humar A et al. Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant 2011; 15: 172-175.
53. Furth S, Neu A, McColley S, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol 1995; 9: 566-568.
54. Hojsak I, Avitzur Y, Mor E et al. Antibody response to influenza vaccine in pediatric liver transplant recipients. Pediatr Infect Dis J 2011; 30: 491-494.
55. Morelon E, Noble CP, Daoud S et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 2010; 28: 6885-6890.
56. Magnani G, Falchetti E, Pollini G et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005; 24: 588-592.
57. Goldschmidt I, Pfister ED, Becker M, Hackl S, Bott OJ, Baumann U. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. J Pediatr 2011; 158: 329-333.
58. Hammarström V, Pauksen K, Svensson H et al. Tetanus immunity in patients with haematological malignancies. Supp Care Cancer 1998; 6: 469-472.
59. von der Hardt K, Jungert J, Beck J, Heininger U. Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents - a retrospective analysis. Vaccine 2000; 18: 2999-3004.
60. Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone B. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis 2003; 35: 851-857.
61. Zignol M, Peracchi M, Tridello G et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101: 635-641.
62. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b. J Pediatr Hematol Oncol 2004; 26: 727-734.
63. Li Volti S, Mauro L, Digregorio F et al. Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. Bone Marrow Transplant 1994; 14: 225-227.
64. Parkkali T, Ölander R-M, Ruutu T et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 1997; 19: 933-938.
65. Enke BU, Bokenkamp A, Offner G, Bartmann P, Brodehl J. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997; 64: 237-241.
66. Florax A, Ehlert K, Becker K, Vormoor J, Groll A. Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: time for universal vaccination? Bone Marrow Transplant 2006; 38: 639-640.
67. Kochethu G, Clark F, Craddock C. Pertussis: should we vaccinate post transplant? Bone Marrow Transplant 2006; 37: 793-794.
68. Papadopoulos E, Young J, Kernan N et al. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (Tdap) in allogeneic transplant (alloHCT) recipients. Blood 2008; 112: 2214.
69. Small TN, Zelenetz AD, Noy A et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1538-1542.
70. Goyal S, Pai SK, Kelkar R, Advani SH. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998; 22: 193-195.
71. Somjee S, Pai S, Kelkar R, Advani S. Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Leuk Res 1999; 23: 365-367.
72. Meral A, Sevinir B, Gunay U. Efficacy of immunization against hepatitis B virus infection in children with cancer. Med Pediatr Oncol 2000; 35: 47-51.
73. Polychronopoulou-Androulakaki S, Panagiotou JP, Kostaridou S, Kyratzopoulou A, Haidas S. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996; 13: 425-431.
74. Yetgin S, Tunc B, Koc A, Toksoy HB, Ceyhan M, Kanra G. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res 2001; 25: 647-649.
75. Jaffe D, Papadopoulos E, Young J et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006; 108: 2470-2475.
76. Onozawa M, Hashino S, Darmanin S et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008; 14: 1226-1230.
77. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72: 272-276.
78. Horlander JC, Boyle N, Manam R et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318: 304-307.
79. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314-320.
80. Duca P, Del Pont JM, D'Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. J Pediatr Gastroenterol Nutr 2001; 32: 168-170.
81. Sanchez-Fueyo A, Rimola A, Grande L et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
82. Angelico M, Di Paolo D, Trinito MO et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-181.
83. Choy BY, Peiris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transplant 2002; 2: 965-969.
84. Dumot JA, Barnes DS, Younossi Z et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94: 1601-1604.
85. Ferreira CT, da Silveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr 2003; 37: 258-261.
86. Kharfan-Dabaja MA, Boeckh M, Wilck MB et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12: 290-299.
87. Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256-1263.
88. Klosky JL, Gamble HL, Spunt SL, Randolph ME, Green DM, Hudson MM. Human papillomavirus vaccination in survivors of childhood cancer. Cancer 2009; 115: 5627-5636.
89. Gershon A, Steinberg S. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989; 320: 892-897.
90. Brunell P, Geiser C, Novelli V, Lipton S, Narkiewicz S. Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia. Pediatrics 1987; 79: 922-927.
91. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 381-383.
92. Chou JF, Kernan NA, Prockop S et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2011; 17: 1708-1713.
93. Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 2010; 45: 1602-1606.
94. Broyer M, Tete M, Guest G, Gagnadoux M, C R. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99: 35-39.
95. Weinberg A, Horslen SP, Kaufman SS et al Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6: 565-568.
96. Kaplan L, Daum R, Smaron M, McCarthy C. Severe measles in immunocompromised patients. JAMA 1992; 267: 1237-1241.
97. Nilsson A, De Milito A, Engstrom P et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002; 109: e91.
98. Ljungman P, Aschan J, Barkholt L et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant 2004; 34: 589-593.
99. Machado CM, de Souza V, Sumita LM, da Rocha I, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant 2005; 35: 787-791.
100. Ljungman P, Fridell E, Lönnqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159: 610-615.
101. Spoulou V, Victoratos P, Ioannidis JP, Grafakos S. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J Infect Dis 2000; 182: 965-969.
102. King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633-636.
103. Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 2004; 33: 1187-1190.
104. Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15: 269-272.
105. Mori K, Kawamura K, Honda M, Sasaki N. Responses in children to measles vaccination associated with perirenal transplantation. Pediatr Int 2009; 51: 617-620.
106. Rio B, Marjanovic Z, Lévy V, Hunault M, Bazarbachi A, Zittoun R. Vaccination for yellow fever after bone marrow transplantation. Bone Marrow Transplant 1996; 17 (suppl. 1): 95.